Holen Sie sich die Stockscreener-App
1.54
3.45%
-0.055
Vorhandelsmarkt:
1.52
-0.02
-1.30%
Schlusskurs vom Vortag:
$1.595
Offen:
$1.59
24-Stunden-Volumen:
79,987
Relative Volume:
0.23
Marktkapitalisierung:
$7.75M
Einnahmen:
$32.96M
Nettoeinkommen (Verlust:
$-4.23M
KGV:
-0.00991
EPS:
-155.3294
Netto-Cashflow:
$-14.00M
1W Leistung:
-0.65%
1M Leistung:
-9.41%
6M Leistung:
-47.44%
1J Leistung:
-77.42%
1-Tages-Spanne:
$1.50
$1.59
1-Wochen-Bereich:
$1.43
$1.6105
52-Wochen-Spanne:
$1.1693
$6.992
Sunshine Biopharma Inc Stock (SBFM) Company Profile
Firmenname
Sunshine Biopharma Inc
Sektor
Telefon
954-515-0810
Adresse
333 LAS OLAS WAY, FORT LAUDERDALE
Vergleichen Sie SBFM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SBFM
Sunshine Biopharma Inc
|
1.54 | 7.75M | 32.96M | -4.23M | -14.00M | -155.33 |
|
RGC
Regencell Bioscience Holdings Ltd
|
14.75 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
154.96 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
9.96 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.68 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.40 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Sunshine Biopharma Inc Aktie (SBFM) Neueste Nachrichten
Sunshine Biopharma (SBFM) Stock Price, News & Analysis - MarketBeat
Sunshine Biopharma (NASDAQ:SBFMW) Stock Price Down 12.6% – Here’s What Happened - Defense World
Sunshine Biopharma (NASDAQ:SBFM) Upgraded to “Hold” at Wall Street Zen - Defense World
Sunshine Biopharma Stock Soars After Launch Of First Biosimilar In $10B Canadian Market: Retail Bulls Charge In - Stocktwits
Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market - ACCESS Newswire
Sunshine Biopharma launches first biosimilar drug in Canadian market - Investing.com Australia
Sunshine Biopharma Challenges $10B Biologics Market With New Cancer Treatment Biosimilar - Stock Titan
Sunshine Biopharma (NASDAQ:SBFMW) Trading Down 3.8% – Here’s Why - Defense World
Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’ - MSN
Sunshine Biopharma Launches Generic Gabapentin for Neuropathic P - GuruFocus
Sunshine Biopharma launches generic anticonvulsant drug in Canada By Investing.com - Investing.com South Africa
Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’ By Stocktwits - Investing.com India
Sunshine Biopharma (SBFM) Expands Portfolio with New Gabapentin Launch | SBFM Stock News - GuruFocus
Sunshine Biopharma launches generic anticonvulsant drug in Canada - Investing.com
Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market - Yahoo Finance
Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees 'Huge Potential' - MENAFN.com
Sunshine Biopharma (NASDAQ:SBFMW) Trading 17.8% Higher – Here’s Why - Defense World
Sunshine Biopharma Sees 18% Revenue Growth in Q1 2025 - TipRanks
Sunshine Biopharma Reports 2025 First Quarter Results, Revenues - GuruFocus
Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year - ACCESS Newswire
Sunshine Biopharma Reports Double-Digit Growth: Q1 Revenue Jumps 18% as Pipeline Expands with 6 New Drugs - Stock Titan
Sunshine Biopharma (NASDAQ:SBFM) Stock Price Up 8% – Here’s Why - Defense World
Sunshine Biopharma launches generic antipsychotic drug - Investing.com Australia
Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia - GuruFocus
Sunshine Biopharma (SBFM) Unveils Generic Antipsychotic Drug in Canada | SBFM Stock News - GuruFocus
Sunshine Biopharma launches generic antipsychotic drug By Investing.com - Investing.com Canada
Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market - ACCESS Newswire
Sunshine Biopharma Challenges $1.2B Antipsychotic Market With New Generic Latuda Alternative - Stock Titan
Certain Warrants of Sunshine Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 4-MAY-2025. - marketscreener.com
Sunshine Biopharma Inc’s Market Journey: Closing Weak at 1.84, Down -18.22 - DWinneX
Sunshine Biopharma (NASDAQ:SBFMW) Stock Price Down 4.5% – Here’s Why - Defense World
There is no doubt that Sunshine Biopharma Inc (SBFM) ticks all the boxes. - Sete News
Sunshine Becomes Latest To Compete On Everolimus In Canada - insights.citeline.com
Sunshine Biopharma Boosts Retail Trader Appeal After Canadian Launch Of Generic Cancer Drug - Asianet Newsable
Sunshine Biopharma Boosts Retail Trader Appeal After Canadian Launch Of Generic Cancer Drug By Stocktwits - Investing.com India
SBFM Stock: A Comprehensive Analysis and Forecast - investchronicle.com
Sunshine Biopharma enters Canadian generic drug market with Everolimus By Investing.com - Investing.com South Africa
Press Release Distribution & PR Platform - ACCESS Newswire
SBFM’s valuation metrics: A comprehensive analysis - uspostnews.com
Sunshine Biopharma (SBFM) Finalizes $2.46 Million Stock Offering - GuruFocus
Sunshine Biopharma Unit Rolls Out Afinitor Alternative Everolimus in Canadian Market - marketscreener.com
Sunshine Biopharma enters Canadian generic drug market with Everolimus - Investing.com
Sunshine Biopharma (SBFM) Launches Generic Everolimus in Canada | SBFM Stock News - GuruFocus
Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion | SBFM Stock News - GuruFocus
Major Cancer Treatment Everolimus Enters Canadian Market: Multiple Cancer Types Targeted in $2.5B Opportunity - Stock Titan
Sunshine Biopharma (SBFM) Launches Generic Everolimus in Canada - GuruFocus
Sunshine Biopharma stock hits 52-week low at $1.24 - Investing.com Australia
Sunshine Biopharma stock hits 52-week low at $1.24 By Investing.com - Investing.com India
Finanzdaten der Sunshine Biopharma Inc-Aktie (SBFM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):